Amryt Pharma plc [AMYT] vs AbbVie [ABBV] Detailed Stock Comparison

Amryt Pharma plc

NASDAQ
Loading...

AbbVie Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amryt Pharma plc wins in 5 metrics, AbbVie Inc. wins in 8 metrics, with 2 ties. AbbVie Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amryt Pharma plc AbbVie Inc. Better
P/E Ratio (TTM) 39.73 83.46 Amryt Pharma plc
Price-to-Book Ratio 2.80 -108.79 Amryt Pharma plc
Debt-to-Equity Ratio 164.32 -21.19 Amryt Pharma plc
PEG Ratio -0.39 -0.01 AbbVie Inc.
EV/EBITDA 0.00 14.31 Tie
Profit Margin (TTM) 52.32% 6.91% Amryt Pharma plc
Operating Margin (TTM) -0.86% 34.11% AbbVie Inc.
EBITDA Margin (TTM) N/A 34.11% N/A
Return on Equity -94.18% 6,225.00% AbbVie Inc.
Return on Assets (TTM) -2.32% 9.81% AbbVie Inc.
Free Cash Flow (TTM) N/A $17.82B N/A
Dividend Yield N/A 3.10% N/A
1-Year Return N/A 19.18% N/A
Price-to-Sales Ratio (TTM) 4.24 5.72 Amryt Pharma plc
Enterprise Value $0 $418.50B AbbVie Inc.
EV/Revenue Ratio 0.00 6.84 Tie
Gross Profit Margin (TTM) 44.86% 72.61% AbbVie Inc.
Revenue per Share (TTM) $5 $35 AbbVie Inc.
Earnings per Share (Diluted) $0.02 $2.37 AbbVie Inc.
Beta (Stock Volatility) N/A 0.36 N/A
Short % of Float N/A 1.27% N/A

Amryt Pharma plc vs AbbVie Inc. Stock Performance Analysis

Loading Price Chart...

AMYT
ABBV

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amryt Pharma plc0.00%0.00%0.00%0.00%0.00%0.00%
AbbVie Inc.0.04%2.58%8.40%22.13%18.90%10.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amryt Pharma plcN/AN/AN/AN/AN/AN/A
AbbVie Inc.19.18%64.26%101.32%279.49%590.09%590.09%

Performance & Financial Health Analysis: Amryt Pharma plc vs AbbVie Inc.

MetricAMYTABBV
Market Information
Market Cap iN/A$351.47B
Market Cap CategoryN/AMega cap
10 Day Avg. Volume i2,376,3856,251,101
90 Day Avg. Volume i1,458,1826,859,587
Last Close$14.70$254.49
52 Week Range$14.70 - $14.71$184.63 - $261.64
% from 52W High-0.07%-2.73%
All-Time High$14.71 (Jan 16, 2025)$261.64 (Jul 02, 2026)
% from All-Time High-0.07%-2.73%
Growth Metrics
Quarterly Revenue Growth-0.11%0.10%
Quarterly Earnings GrowthN/A0.10%
Financial Health
Profit Margin (TTM) i0.52%0.07%
Operating Margin (TTM) i-0.01%0.34%
Return on Equity (TTM) i-0.94%62.25%
Debt to Equity (MRQ) i164.32-21.19
Cash & Liquidity
Book Value per Share (MRQ)$0.02$-1.85
Cash per Share (MRQ)$1.30$2.97
Operating Cash Flow (TTM) i$-29,023,000$19.03B
Levered Free Cash Flow (TTM) i$-18,171,000$18.34B
Dividends
Last 12-Month Dividend Yield iN/A3.10%
Last 12-Month Dividend iN/A$6.65

Valuation & Enterprise Metrics Analysis: Amryt Pharma plc vs AbbVie Inc.

MetricAMYT (Mar 31, 2025)ABBV (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i39.7383.46
Forward P/E i-490.0012.30
PEG Ratio i-0.39-0.01
Price to Sales (TTM) i4.245.72
Price to Book (MRQ) i2.80-108.79
Market Capitalization
Market Capitalization i$942.77M$351.47B
Enterprise Value i$0$418.50B
Enterprise Value Metrics
Enterprise to Revenue i0.006.84
Enterprise to EBITDA i0.0014.31
Risk & Other Metrics
Beta iN/A0.36
Book Value per Share (MRQ) i$0.02$-1.85

Financial Statements Comparison: Amryt Pharma plc vs AbbVie Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMYTABBV (2025)
Revenue/Sales iN/A61.16B
Cost of Goods Sold iN/A18.20B
COGS % of Revenue i-29.8%
Gross Profit iN/A42.96B
Gross Margin i-70.2%
Research & Development iN/A9.10B
Operating Income (EBIT) iN/A20.09B
Operating Margin i-32.8%
EBITDA iN/A22.70B
EBITDA Margin i-37.1%
Pre-Tax Income iN/A6.60B
Pre-Tax Income % of Revenue i-10.8%
Income Tax iN/A2.36B
Income Tax % of Revenue i-3.9%
Net Income (Profit) iN/A4.23B
Profit Margin i-6.9%

Balance Sheet & Liquidity Metrics

MetricAMYTABBV (2025)
Cash & Equivalents iN/A5.23B
Total Current Assets iN/A29.06B
Total Current Assets % of Revenue i-47.5%
Total Current Liabilities iN/A43.29B
Total Current Liabilities % of Revenue i-70.8%
Long-Term Debt iN/A58.94B
Long-Term Debt % of Revenue i-96.4%
Total Shareholders Equity iN/A-3.23B
Retained Earnings iN/A-15.49B
Retained Earnings % of Revenue i--25.3%
Property, Plant & Equipment iN/A8.79B

Cash Flow Statement Comparison

MetricAMYTABBV (2025)
Operating Cash Flow iN/A19.94B
Operating Cash Flow % of Revenue i-32.6%
Capital Expenditures iN/A-1.21B
Free Cash Flow iN/A17.82B
FCF Margin i-29.1%
Debt Repayment iN/A-9.60B
Common Stock Repurchase iN/A-980.00M

Short Interest & Institutional Ownership Analysis

MetricAMYTABBV
Shares Short iN/A20.13M
Short Ratio iN/A2.67
Short % of Float iN/A1.27%
Shares Outstanding i64.13M1.77B
Float Shares iN/A1.77B
% Held by Insiders iN/A0.12%
% Held by Institutions iN/A76.78%
% Held by Public iN/A23.10%

Dividend Analysis & Yield Comparison: Amryt Pharma plc vs AbbVie Inc.

MetricAMYTABBV
Last 12-Month Dividend iN/A$6.65
Last 12-Month Dividend Yield iN/A3.10%
3-Year Avg Annual Dividend iN/A$6.31
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$18.93
Ex-Dividend DateN/AJan 16, 2026